Oral versus intravenous steroids for treatment of relapses in multiple sclerosis - Burton, JM - 2012
| Cochrane Library Skip to Content Cookies Our site uses cookies to improve your experience …

Methylprednisolone plays an important role in the current treatment of multiple sclerosis
(MS), particularly in the acute phase of relapse. It acts in various ways to decrease the …

We conducted a meta-analysis of randomized controlled clinical trials on steroid treatment
for multiple sclerosis and optic neuritis. Of the 25 trials comparing steroids and controls …

Background Apoptosis is supposed to contribute to the elimination of T cells from the
inflamed central nervous system in the natural disease course of multiple sclerosis (MS). In …

Studies in adult patients with multiple sclerosis (MS) suggest significant benefit of early
treatment initiation. However, there are no approved therapies for children and adolescents …

Multiple sclerosis is an autoimmune disease with classical traits of demyelination, axonal
damage, and neurodegeneration. The migration of autoimmune T cells and macrophages …

Objective: To determine whether lesion evolution in relapsing-remitting multiple sclerosis
(RRMS) patients is altered by treatment with interferonβ-1b (IFNb-1b) or by intravenous …

Objective: To compare the tolerability and efficacy of two doses of IV methylprednisolone in
patients with secondary-progressive MS. Methods: IV methylprednisolone administered in …

Relapses of multiple sclerosis (MS) are treated commonly with high-dose intravenous
methylprednisolone (MP) given over a period of 3–5 days. The mechanisms responsible for …

Bone mineral density (BMD) is affected in young adults with multiple sclerosis (MS), which
leads to disabling disease. We aimed to show changes that were independent of …